These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 22238982)

  • 1. [Effect of cardiovascular drugs on vasodilating endothelial function in animals with experimental deficiency of sex hormones].
    Voronkov AV; Tiurenkov IN
    Eksp Klin Farmakol; 2011; 74(10):23-5. PubMed ID: 22238982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nitric oxide mechanisms of nebivolol.
    Maffei A; Lembo G
    Ther Adv Cardiovasc Dis; 2009 Aug; 3(4):317-27. PubMed ID: 19443516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endothelial dysfunction, angiotensin-converting enzyme inhibitors and calcium antagonists.
    López-Jaramillo P; Casas JP
    J Hum Hypertens; 2002 Mar; 16 Suppl 1():S34-7. PubMed ID: 11986891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nebivolol: a highly selective beta1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide.
    Gupta S; Wright HM
    Cardiovasc Ther; 2008; 26(3):189-202. PubMed ID: 18786089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol.
    Dessy C; Saliez J; Ghisdal P; Daneau G; Lobysheva II; Frérart F; Belge C; Jnaoui K; Noirhomme P; Feron O; Balligand JL
    Circulation; 2005 Aug; 112(8):1198-205. PubMed ID: 16116070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endothelium-independent vasodilation effect of di- and tri-peptides in thoracic aorta of Sprague-Dawley rats.
    Tanaka M; Tokuyasu M; Matsui T; Matsumoto K
    Life Sci; 2008 Apr; 82(15-16):869-75. PubMed ID: 18329669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular effects of newer cardiovascular drugs: focus on nebivolol and ACE-inhibitors.
    Lüscher TF; Spieker LE; Noll G; Cosentino F
    J Cardiovasc Pharmacol; 2001 Dec; 38 Suppl 3():S3-11. PubMed ID: 11811390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement of left ventricular diastolic function induced by β-blockade: a comparison between nebivolol and metoprolol.
    Fang Y; Nicol L; Harouki N; Monteil C; Wecker D; Debunne M; Bauer F; Lallemand F; Richard V; Thuillez C; Mulder P
    J Mol Cell Cardiol; 2011 Aug; 51(2):168-76. PubMed ID: 21640121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective effects of ACE inhibitors on vascular endothelial dysfunction induced by exogenous advanced oxidation protein products in rats.
    Chen SX; Song T; Zhou SH; Liu YH; Wu SJ; Liu LY
    Eur J Pharmacol; 2008 Apr; 584(2-3):368-75. PubMed ID: 18334254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nebivolol: the somewhat-different beta-adrenergic receptor blocker.
    Münzel T; Gori T
    J Am Coll Cardiol; 2009 Oct; 54(16):1491-9. PubMed ID: 19815121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular risk, drugs and erectile function--a systematic analysis.
    Baumhäkel M; Schlimmer N; Kratz M; Hackett G; Jackson G; Böhm M
    Int J Clin Pract; 2011 Mar; 65(3):289-98. PubMed ID: 21314866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different pharmacological properties of two enantiomers in a unique beta-blocker, nebivolol.
    Ignarro LJ
    Cardiovasc Ther; 2008; 26(2):115-34. PubMed ID: 18485134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart.
    Rozec B; Erfanian M; Laurent K; Trochu JN; Gauthier C
    J Am Coll Cardiol; 2009 Apr; 53(17):1532-8. PubMed ID: 19389564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term treatment with a beta-blocker with vasodilative capacities improves intrarenal endothelial function in experimental renal failure.
    Gschwend S; Haug MB; Nierhaus M; Schulz A; Vetter R; Kossmehl P; Orzechowski HD; Scholze J; Rothermund L; Kreutz R
    Life Sci; 2009 Sep; 85(11-12):431-7. PubMed ID: 19635487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of nitric oxide in improving endothelial function and cardiovascular health: focus on nebivolol.
    Bakris GL; Basile JN; Giles TD; Taylor AA
    Am J Med; 2010 Jul; 123(7 Suppl 1):S2-8. PubMed ID: 20609695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Angiotensin-converting enzyme inhibition and statin treatment on inflammatory markers and endothelial functions in patients with longterm rheumatoid arthritis.
    Tikiz C; Utuk O; Pirildar T; Bayturan O; Bayindir P; Taneli F; Tikiz H; Tuzun C
    J Rheumatol; 2005 Nov; 32(11):2095-101. PubMed ID: 16265685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Endothelial protection].
    Bossaller C; Auch-Schwelck W; Graf K; Gräfe M; Fleck E
    Vasa Suppl; 1991; 33():51. PubMed ID: 1788760
    [No Abstract]   [Full Text] [Related]  

  • 18. Angiotensin-converting enzyme inhibition and angiotensin AT1-receptor antagonism equally improve endothelial vasodilator function in L-NAME-induced hypertensive rats.
    De Gennaro Colonna V; Rigamonti A; Fioretti S; Bonomo S; Manfredi B; Ferrario P; Bianchi M; Berti F; Muller EE; Rossoni G
    Eur J Pharmacol; 2005 Jun; 516(3):253-9. PubMed ID: 15963975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of nebivolol on cardiovascular changes associated with a rat model of insulin-resistance.
    Renna N; Risler N; Cruzado M; Gonzalez S; Lama C; Miatello RM
    Cell Mol Biol (Noisy-le-grand); 2005 Nov; 51(6):531-7. PubMed ID: 16309577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic interventions in endothelial dysfunction: endothelium as a target organ.
    Cooke JP
    Clin Cardiol; 1997 Nov; 20(11 Suppl 2):II-45-51. PubMed ID: 9422852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.